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Re: ‘Prothrombin G20210 Mutation and Lower Extremity
Peripheral Arterial Disease: A Systematic Review and
Meta-analysis’
Vasquez et al.1 showed that prothrombin G20210 mutation
is signiﬁcantly elevated in patients with peripheral occlusive
arterial disease (POAD) suffering from critical limb ischemia
(CLI) but not in the others. Interestingly, this mutation has
been reported to be more prevalent in patients with
Buerger’s disease.2,3 Avcu et al.2 found an increased fre-
quency of the G20210 mutation in Buerger’s disease (OR
7.98, 2.45e25.13). Buerger’s disease is characterized by
diffuse arterial thrombosis and a severe clinical picture,
most often at the CLI stage. In a recently published case
control study among patients with premature POAD the
author’s team found that G20210 mutation was signiﬁcantly
more frequent in Buerger’s disease (4.2% vs. 1.7 in con-
trols).3 This difference was not found for atherosclerosis
related POAD (2.6%). When compared with the 64 POAD
patients, the 49 with Buerger’s disease had CLI in 88%
versus 28% in atherosclerosis related POAD. As suggested
by Vasquez et al.,1 G20210 mutation might be one among
several factors favouring thrombosis and leading to CLI in
POAD, and prospective cohort studies would be useful to
evaluate the role of this mutation to predict progression in
POAD.
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Response to ‘Re: Prothrombin G20210A Mutation and
Lower Extremity Peripheral Arterial Disease. A Systematic
Review and Meta-analysis’
We read with interest the letter by Boulon et al.1 The pro-
posed association between prothrombin G20210A and
thromboangiitis obliterans is very interesting. Prior studies
have suggested that prothrombin G20210A interacts with
other cardiovascular risk factors (especially smoking) to in-
crease the risk of vascular events,2 and this interaction could
further explain the association of prothrombin G20210A and
thromboangiitis obliterans seen by Bérard et al. and Avcu et
al.3,4 The literature search conducted in our systematic re-
view did not identify the study by Bérard et al.3,5; had the
study been included there would have been no changes in
the association of lower extremity peripheral arterial disease
(PAD) prothrombin G20210A (pooled random effect odds
ratio 1.68 [95% conﬁdence interval 0.94e3.00]; I2 52.1%; p
¼ .08). Furthermore, the addition of the study by Bérard et
al. does not modify the association between prothrombin
G20210A and critical limb ischemia secondary to PAD (even
in the absence of positive cases).3 Finally, we agree that
well-designed prospective cohort studies are needed to
evaluate the role of prothrombin G20210A in the progres-
sion and outcome of patients with PAD.
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Re: ‘Association of Venous Disorders with Leg Symptoms:
Results from the Bonn Vein Study 1’
In their well deﬁned population based cross sectional study,
Wrona et al.1 have evaluated the association between
chronic venous disorders like varicose veins and chronic
venous insufﬁciency, and leg symptoms. Symptoms such as
tightness, feeling of heaviness, swelling, itching, and pain
after standing or sitting have been found to be associated
with varicose veins and chronic venous insufﬁciency. How-
ever, muscle cramps and pain during walking have been
found to be associated with varicose veins but not with
chronic venous insufﬁciency. Restless legs and muscle
cramps are not, or less associated, with varicose veins,
chronic venous insufﬁciency, or C class. Finally, they have
concluded that restless legs and muscle cramps should no
longer be considered as “venous leg symptoms”.
Assessment of venous symptoms and making a differ-
ential diagnosis in patients suffering from a variety ofsymptoms is a big challenge in daily clinical practice. In
accordance with Wrona et al.,1 the general agreement is
that these symptoms themselves show poor sensitivity and
speciﬁcity for venous insufﬁciency but are ordinarily
recognized as symptoms of a functional disorder.2,3
Several factors might play role in the diagnostic inefﬁcacy
of venous symptoms. Firstly, studies have mostly focused on
either the prevalence of varicose veins or duplex scanning
in assessing venous insufﬁciency irrespective of symptoms.4
Secondly, a high co-existence rate of co-morbid disease,
such as peripheral artery disease, arthrosis, and obesity,
makes the assessment of lower limb symptoms more
complex. Diabetes mellitus, which has never been
mentioned in the literature, is likely to play a role as an
underlying cause in the pathogenesis of aching legs, burning
sensation, swelling, or itching.5 Likewise neither population
based nor symptom oriented studies have ever included
patients’ medication in their analysis. Someone would
expect to see the positive or the negative inﬂuence of drugs
received such as diuretics, calcium antagonists, oral anti-
diabetic medications, and painkillers on venous symptoms.
In this regard, it is too early to state that muscle cramps,
and restless legs should no longer be considered as venous
leg symptoms. Instead of evaluating each symptom indi-
vidually, a comprehensive scoring system is needed for
assessing or combining symptoms as a whole.
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